GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Net Current Asset Value

NetraMark Holdings (XCNQ:AIAI) Net Current Asset Value : C$0.00 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

NetraMark Holdings's net current asset value per share for the quarter that ended in Jun. 2024 was C$0.00.

The historical rank and industry rank for NetraMark Holdings's Net Current Asset Value or its related term are showing as below:

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of NetraMark Holdings was 51.00. The lowest was 8.79. And the median was 18.79.

XCNQ:AIAI's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.42
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

NetraMark Holdings Net Current Asset Value Historical Data

The historical data trend for NetraMark Holdings's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Net Current Asset Value Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Net Current Asset Value
0.06 0.19 -0.02 0.02

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 0.01 - -

Competitive Comparison of NetraMark Holdings's Net Current Asset Value

For the Health Information Services subindustry, NetraMark Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NetraMark Holdings's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's Price-to-Net-Current-Asset-Value falls into.



NetraMark Holdings Net Current Asset Value Calculation

NetraMark Holdings's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Sep. 2023 is calculated as

Net Current Asset Value Per Share(A: Sep. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.91-0.824-0-0)/65.6379
=0.02

NetraMark Holdings's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2024 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.523-0.238-0-0)/69.2971
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NetraMark Holdings  (XCNQ:AIAI) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


NetraMark Holdings Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of an Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Luigi Gino Demichele Director
Andrew Parks Director
Kevin Robert Taylor Director
George Achilleos Director, Senior Officer
Joseph Geraci Senior Officer
Cook Douglas J. Senior Officer

NetraMark Holdings Headlines

No Headlines